These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39365581)

  • 21. Racial and Ethnic Disparities in Maternal and Infant Outcomes Among Opioid-Exposed Mother-Infant Dyads in Massachusetts (2017-2019).
    Peeler M; Gupta M; Melvin P; Bryant AS; Diop H; Iverson R; Callaghan K; Wachman EM; Singh R; Houghton M; Greenfield SF; Schiff DM
    Am J Public Health; 2020 Dec; 110(12):1828-1836. PubMed ID: 33058701
    [No Abstract]   [Full Text] [Related]  

  • 22. The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder.
    Dever JA; Hertz MF; Dunlap LJ; Richardson JS; Wolicki SB; Biggers BB; Edlund MJ; Bohm MK; Turcios D; Jiang X; Zhou H; Evans ME; Guy GP
    Public Health Rep; 2024; 139(4):484-493. PubMed ID: 38268479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Perceived Access and Treatment Knowledge on Medication Preferences for Opioid Use Disorder.
    Jaffe K; Patel S; Chen L; Slat S; Bohnert A; Lagisetty P
    Subst Use Addctn J; 2024 Oct; 45(4):706-715. PubMed ID: 38828548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV; Levin FR; Reilly MP; El-Bassel N
    J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
    Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
    Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
    Bello JK; Xu KY; Salas J; Bedrick BS; Grucza RA
    J Gen Intern Med; 2024 Jun; 39(8):1342-1348. PubMed ID: 38424347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
    ; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
    JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
    Saulle R; Vecchi S; Gowing L
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid Overdose After Medication for Opioid Use Disorder Initiation Following Hospitalization or ED Visit.
    Weiner SG; Little K; Yoo J; Flores DP; Hildebran C; Wright DA; Ritter GA; El Ibrahimi S
    JAMA Netw Open; 2024 Jul; 7(7):e2423954. PubMed ID: 39037812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
    Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
    JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duration of medication for opioid use disorder during pregnancy and postpartum by race/ethnicity: Results from 6 state Medicaid programs.
    Austin AE; Durrance CP; Ahrens KA; Chen Q; Hammerslag L; McDuffie MJ; Talbert J; Lanier P; Donohue JM; Jarlenski M
    Drug Alcohol Depend; 2023 Jun; 247():109868. PubMed ID: 37058829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Buprenorphine for managing opioid withdrawal.
    Gowing L; Ali R; White JM; Mbewe D
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD002025. PubMed ID: 28220474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees.
    Stein BD; Dick AW; Sorbero M; Gordon AJ; Burns RM; Leslie DL; Pacula RL
    Subst Abus; 2018; 39(4):419-425. PubMed ID: 29932847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations.
    Husain JM; Cromartie D; Fitzelle-Jones E; Brochier A; Borba CPC; Montalvo C
    J Subst Abuse Treat; 2023 Jan; 144():108918. PubMed ID: 36403456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S; Sun L; Vakkalanka JP
    Am J Emerg Med; 2024 Aug; 82():52-56. PubMed ID: 38795424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multimodal assessment of sleep in men and women during treatment for opioid use disorder.
    Finan PH; Mun CJ; Epstein DH; Kowalczyk WJ; Phillips KA; Agage D; Smith MT; Preston KL
    Drug Alcohol Depend; 2020 Feb; 207():107698. PubMed ID: 31816489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.